Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1922496 | 0.84 | NAAA (0.33) | BACE1 | |
| SCHEMBL1922927 | 0.79 | ALDH1A1 (0.32) | MEN1KMT2A | |
| SCHEMBL22678373 | 0.76 | MRGPRX4 (0.38) | BACE1MEN1PKMKMT2A | |
| SCHEMBL4996802 | 0.75 | IDO1 (0.38) | BACE1MEN1PKMKMT2A | |
| SCHEMBL22517612 | 0.75 | KDM5A (0.40) | BACE1MEN1PKMKMT2A | |
| SCHEMBL29383016 | 0.75 | NOS3 (0.36) | BACE1MEN1PKMKMT2A | |
| SCHEMBL5373425 | 0.75 | MEN1 (0.49) | BACE1MEN1PKMKMT2A | |
| SCHEMBL8936718 | 0.75 | NOS3 (0.36) | BACE1MEN1PKMKMT2A | |
| SCHEMBL14008752 | 0.74 | GABRA1 (0.50) | MEN1KMT2A | |
| SCHEMBL23322944 | 0.72 | ALDH1A1 (0.34) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456170-B2 | Triazolobenzodiazepines and their use as vasopressin antagonists | PFIZER INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456170-B2 | Triazolobenzodiazepines and their use as vasopressin antagonists | PFIZER INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070249585-A1 | Triazolobenzodiazepines and Their Use as Vasopressin Antagonists | PFIZER INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070249585-A1 | Triazolobenzodiazepines and Their Use as Vasopressin Antagonists | PFIZER INC. | 2007-10-25 | — | — | US | disclosed |
| EP-1784408-A1 | TRIAZOLOBENZODIAZEPINES AND THEIR USE AS VASOPRESSIN ANTAGONISTS | Pfizer Limited (GB) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006021882-A1 | TRIAZOLOBENZODIAZEPINES AND THEIR USE AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249585-A1 | Triazolobenzodiazepines and Their Use as Vasopressin Antagonists | AVPR2, AVPR1A, AVPR1B | BACE1 2994/4885MEN1 915/4885PKM 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.